Implanted Vagus Nerve Stimulation to Promote MS Remyelination

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodegenerative disorders like multiple sclerosis primarily focus on managing symptoms and slowing disease progression, with no effective therapies to reverse demyelination or promote remyelination, and there is a need for non-drug therapies to address inflammation.

Innovation Solution

Vagus nerve stimulation (VNS) is applied with electrical stimulation between 0.25 mA and 5 mA at a low duty cycle to reduce demyelination and promote remyelination, using biomarkers to adjust the dose and timing, and can be combined with pharmacological agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used to manage symptoms and slow disease progression, then patient quality of life is maintained, but demyelination cannot be reversed and remyelination does not occur

Engineering Contradiction:

Improvedisease progression controlVSAvoidmyelin integrity

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

Instead of only suppressing demyelination and slowing progression, the invention applies vagus nerve stimulation to actively reverse demyelination and promote remyelination. The stimulation triggers oligodendrocyte progenitor cell differentiation and myelin regeneration, fundamentally inverting the conventional approach from passive protection to active restoration.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The invention replaces pharmacological interventions with a non-drug therapy mechanism. Vagus nerve stimulation uses electrical stimulation to activate neural pathways that modulate inflammation and promote remyelination, substituting the need for continuous medication with a device-based therapeutic mechanism.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Object-generated harmful factors

If pharmacological agents are used to treat MS, then disease activity is reduced, but inflammation cannot be effectively resolved and remyelination is not promoted

Engineering Contradiction:

Improveinflammation reductionVSAvoidmyelin regeneration

Core Design Contradiction:

Object-generated harmful factorsVSStability of the object's composition

Solution Approach 1:

The invention substitutes pharmacological anti-inflammatory agents with vagus nerve stimulation that resolves inflammation through neural pathway modulation. The stimulation activates the cholinergic anti-inflammatory pathway, providing non-drug mediated inflammation resolution while simultaneously promoting remyelination.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The invention changes the therapeutic parameter from pharmacological concentration to electrical stimulation parameters (current amplitude, pulse width, frequency). By adjusting these parameters, the system achieves both inflammation resolution and remyelination promotion without the limitations of drug-based approaches.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If continuous electrical stimulation is applied to the vagus nerve, then therapeutic effect is maintained, but energy consumption increases and device battery life decreases

Engineering Contradiction:

Improvetherapeutic effect consistencyVSAvoidpower consumption

Core Design Contradiction:

ReliabilityVSUse of energy by moving object

Solution Approach 1:

The invention employs periodic, intermittent vagus nerve stimulation rather than continuous stimulation. The device delivers stimulation pulses at optimized intervals, maintaining therapeutic effectiveness while significantly reducing energy consumption. This periodic action allows the system to achieve cumulative therapeutic benefits without requiring continuous power input.

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

The invention optimizes stimulation parameters including current amplitude (0.25-5 mA), pulse width, and duty cycle to maximize therapeutic efficacy while minimizing energy consumption. By carefully tuning these parameters, the system achieves effective treatment with reduced power requirements, extending battery life between charges.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

VNS effectively reduces demyelination and increases remyelination, demonstrating clinical benefits and molecular pathways that modulate inflammation and improve disease progression.

Implementation Method 1

applying electrical stimulation of between about 0.25 mA and about 5 mA at a duty cycle of less than 10 percent to the patient's vagus nerve

Methodology Applied

Scientific EffectElectrical stimulation: Conduction (electrical)

Data Source

PatentUS20250288808A1Treatment of multiple sclerosis

Publication Date: 2025.09.18 SETPOINT MEDICAL CORP

AI summary

Method for reversing demyelination in a patient having a demyelinating disorder may include detecting one or more biomarkers for demyelination from the patient, receiving, in an implanted vagus nerve stimulator, a command to apply a remyelinating stimulation to the patient based on a level of the detected one or more biomarkers for demyelination; and applying electrical stimulation to the patient's vagus nerve from the implanted vagus nerve stimulator to reverse demyelination and increase remyelination of the patient's nerves. The electrical stimulation may be adjusted based on the level of the detected one or more biomarkers.